Company intelligence / Profile preview
Sana Biotechnology
Seattle, Washington, United Statessana.com ↗
- Ownership
- Public · SANA
- Employees
- ~375
- Development stage
- Phase 1
01
Overview
Sana has initiated Phase I trials with its lead allogeneic CAR-T candidates targeting oncology and autoimmune indications. Initial human data are expected through late 2024 into early/mid–2025. Preclinical results have shown promising immune evasion properties using the HIP platform. The company also has INDs submitted or planned for additional programs including type I diabetes.
- Therapeutic areas
- OncologyImmunologyEndocrinologyNeurology
- Modalities
- Allogeneic CAR-T cells (engineered T cells)Hypoimmune-modified cell therapies (HIP platform)Pancreatic islet cell therapyIn vivo and ex vivo gene editing/cell engineering
- Industry
- Biotech
02
Drug pipeline
21 assets20 more assets in the full pipeline.
03
Partnerships
Vertex Pharmaceuticals—collaboration on hypoimmune platform for type I diabetes therapy development.
04
Financials
- Market cap
- $700.5M
- Total revenue
- $0
- Enterprise value
- $632.6M
Beyond the preview
Go deeper on Sana Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sana Biotechnology.